You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCimetidine
Accession NumberDB00501  (APRD00568)
TypeSmall Molecule
GroupsApproved
Description

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]

Structure
Thumb
Synonyms
1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine
2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine
Cimetag
Cimetidin
Cimetidina
Cimétidine
Cimetidinum
N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine
N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine
Tagamet hb 200
Ulcerfen
External Identifiers
  • SKF 92334
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cimetidine 200 Tab 200mgtablet200 mgoralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 300mgtablet300 mgoralPro Doc Limitee1983-12-312010-07-13Canada
Cimetidine Tab 400mgtablet400 mgoralPro Doc Limitee1984-12-312009-07-23Canada
Cimetidine Tab 600mgtablet600 mgoralPro Doc Limitee1984-12-312012-07-23Canada
Dom-cimetidinetablet200 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cimetidinetablet800 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cimetidinetablet600 mgoralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidinetablet400 mgoralDominion Pharmacal2000-06-19Not applicableCanada
Dom-cimetidinetablet300 mgoralDominion Pharmacal2000-06-19Not applicableCanada
Gen-cimetidine Tablets 200mgtablet200 mgoralGenpharm Ulc1997-05-302009-08-05Canada
Mylan-cimetidinetablet300 mgoralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidinetablet800 mgoralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidinetablet600 mgoralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Mylan-cimetidinetablet400 mgoralMylan Pharmaceuticals Ulc1997-05-30Not applicableCanada
Novo-cimetinetablet800 mgoralTeva Canada Limited1987-12-31Not applicableCanada
Novo-cimetinetablet600 mgoralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetinetablet400 mgoralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetinetablet300 mgoralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetinetablet200 mgoralTeva Canada Limited1983-12-31Not applicableCanada
Novo-cimetine Injectionsolution150 mgintramuscular; intravenousTeva Canada Limited1997-09-022015-04-30Canada
Nu-cimet Tab 200mgtablet200 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 300mgtablet300 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 400mgtablet400 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Nu-cimet Tab 600mgtablet600 mgoralNu Pharm Inc1990-12-312012-09-04Canada
Peptol Tab 200mgtablet200 mgoralCarter Horner Corp.1981-12-312004-07-09Canada
Peptol Tab 300mgtablet300 mgoralCarter Horner Corp.1981-12-312004-07-09Canada
Peptol Tab 400mgtablet400 mgoralCarter Horner Corp.1982-12-312004-07-09Canada
Peptol Tab 600mgtablet600 mgoralCarter Horner Corp.1983-12-312004-07-09Canada
Peptol Tab 800mgtablet800 mgoralCarter Horner Corp.1984-12-312004-07-09Canada
PMS-cimetidinetablet800 mgoralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidinetablet600 mgoralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidinetablet400 mgoralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidinetablet300 mgoralPharmascience Inc1998-02-05Not applicableCanada
PMS-cimetidinetablet200 mgoralPharmascience Inc1998-02-05Not applicableCanada
Tagamet 300tablet300 mgoralGlaxosmithkline Inc1992-12-312002-02-04Canada
Tagamet 400tablet400 mgoralGlaxosmithkline Inc1993-12-312002-02-04Canada
Tagamet 600tablet600 mgoralGlaxosmithkline Inc1992-12-312002-02-04Canada
Tagamet Infusion 6mg/mlliquid6 mgintravenousSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-311999-03-24Canada
Tagamet Inj 150mg/mlliquid150 mgintramuscular; intravenousSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1995-12-311998-08-31Canada
Tagamet Liq 300mg/5mlliquid300 mgoralSmith Kline & French Canada Ltd.1982-12-311997-08-15Canada
Tagamet Liquid 60mg/mlliquid60 mgoralGlaxosmithkline Inc1993-12-312002-07-31Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Cimetidine Tab 200mgtablet200 mgoralApotex Inc1982-12-31Not applicableCanada
Apo Cimetidine Tab 300mgtablet300 mgoralApotex Inc1982-12-31Not applicableCanada
Apo Cimetidine Tab 400mgtablet400 mgoralApotex Inc1983-12-31Not applicableCanada
Apo Cimetidine Tab 600mgtablet600 mgoralApotex Inc1983-12-31Not applicableCanada
Apo-cimetidine Oral Solutionliquid300 mgoralApotex Inc2001-01-05Not applicableCanada
Apo-cimetidine Tab 800mgtablet800 mgoralApotex Inc1988-12-31Not applicableCanada
Cimetidinetablet, film coated400 mg/1oralPreferred Pharmaceuticals, Inc2011-07-062016-04-05Us
Cimetidinetablet400 mg/1oralREMEDYREPACK INC.2011-07-142016-04-05Us
Cimetidinetablet, film coated400 mg/1oralBlenheim Pharmacal, Inc.2014-01-142016-04-05Us
Cimetidinetablet, film coated300 mg/1oralTeva Pharmaceuticals USA Inc2003-11-242016-04-23Us
Cimetidinetablet, film coated400 mg/1oralCarilion Materials Management2004-02-022016-04-05Us
Cimetidinetablet, film coated400 mg/1oralProficient Rx LP2004-02-022016-04-05Us
Cimetidinetablet400 mg/1oralREMEDYREPACK INC.2010-11-242016-04-05Us
Cimetidinetablet400 mg/1oralLiberty Pharmaceuticals, Inc.2010-11-242016-04-23Us
Cimetidinetablet, film coated300 mg/1oralCarilion Materials Management2003-11-242016-04-05Us
Cimetidinetablet, film coated400 mg/1oralAv Kare, Inc.2013-07-232016-04-05Us
Cimetidinetablet, film coated800 mg/1oralMylan Pharmaceuticals Inc.1994-05-172016-04-23Us
Cimetidinetablet, film coated200 mg/1oralCarilion Materials Management1994-05-172016-04-05Us
Cimetidinetablet, film coated400 mg/1oralPd Rx Pharmaceuticals, Inc.2011-05-042016-04-05Us
Cimetidinetablet, film coated400 mg/1oralAidarex Pharmaceuticals LLC2004-02-022016-04-05Us
Cimetidinetablet, film coated400 mg/1oralMylan Pharmaceuticals Inc.1994-05-172016-04-23Us
Cimetidinetablet, film coated400 mg/1oralDispensing Solutions, Inc.2010-05-262016-04-05Us
Cimetidinetablet, film coated800 mg/1oralPhysicians Total Care, Inc.1994-05-232016-04-05Us
Cimetidinetablet, film coated800 mg/1oralSTAT Rx USA LLC2010-05-262016-04-05Us
Cimetidinetablet, film coated300 mg/1oralMylan Pharmaceuticals Inc.1994-05-172016-04-23Us
Cimetidinetablet, film coated400 mg/1oralPhysicians Total Care, Inc.1994-07-252016-04-05Us
Cimetidinetablet, film coated400 mg/1oralSTAT Rx USA LLC2010-05-262016-04-05Us
Cimetidinetablet, film coated200 mg/1oralMylan Pharmaceuticals Inc.1994-05-172016-04-23Us
Cimetidinetablet, film coated300 mg/1oralbryant ranch prepack2003-11-242016-04-05Us
Cimetidinetablet, film coated300 mg/1oralPhysicians Total Care, Inc.1994-06-222016-04-05Us
Cimetidinetablet, film coated300 mg/1oralSTAT Rx USA LLC1994-05-172016-04-05Us
Cimetidinetablet, film coated800 mg/1oralTeva Pharmaceuticals USA Inc2003-12-062016-04-23Us
Cimetidinetablet, film coated400 mg/1oralbryant ranch prepack2010-10-012016-04-05Us
Cimetidinetablet, film coated300 mg/1oralREMEDYREPACK INC.2014-08-012016-04-05Us
Cimetidinetablet, film coated800 mg/1oralbryant ranch prepack2003-12-062016-04-05Us
Cimetidinetablet, film coated300 mg/1oralREMEDYREPACK INC.2013-05-282016-04-05Us
Cimetidinetablet, film coated300 mg/1oralAv Kare, Inc.2016-01-122016-04-05Us
Cimetidinetablet, film coated300 mg/1oralBlenheim Pharmacal, Inc.2014-01-142016-04-05Us
Cimetidinetablet, film coated400 mg/1oralTeva Pharmaceuticals USA Inc2004-02-022016-04-23Us
Cimetidine Hydrochloridesolution300 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1997-03-122016-04-05Us
Cimetidine Hydrochloride Oral Solutionsolution300 mg/5mLoralHi Tech Pharmacal Co., Inc.1997-10-282016-04-05Us
Good Sense Heartburn Relieftablet200 mg/1oralbryant ranch prepack2002-12-302016-04-05Us
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acid Reducertablet200 mg/1oralKroger Company2015-10-212016-04-05Us
Acid Reducertablet200 mg/1oralRite Aid Corporation2005-07-082016-04-05Us
Cimetidine Acid Reducertablet200 mg/1oralWalgreen Company2001-03-272016-04-23Us
Dg Health Heartburn Relieftablet200 mg/1oralDolgencorp, LLC2010-03-022016-04-05Us
Equaline Acid Reducertablet200 mg/1oralSupervalu Inc2004-09-152016-04-05Us
Equate Cimetidinetablet200 mg/1oralWal Mart Stores Inc2006-09-272016-04-05Us
Gaviscon All-nighttablet100 mgoralGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Gaviscon Preventtablet100 mgoralGlaxosmithkline Consumer Healthcare Inc.1998-08-172002-07-31Canada
Gaviscon Prevent Extra Strengthtablet200 mgoralGlaxosmithkline Consumer Healthcare Inc.Not applicableNot applicableCanada
Good Neighbor Pharmacy Heartburn Relieftablet200 mg/1oralAmerisource Bergen2000-01-052016-04-05Us
Good Sense Heartburn Relieftablet200 mg/1oralL. Perrigo Company2002-12-302016-04-23Us
Harris Teeter Acid Reducertablet200 mg/1oralHarris Teeter, LLC2015-03-302016-04-05Us
Heartburn Relieftablet200 mg/1oralCVS Pharmacy2000-01-142016-04-05Us
Heartburn Relieftablet200 mg/1oralFamily Dollar Services Inc2000-09-182016-04-05Us
Heartburn Relieftablet200 mg/1oralMeijer Distribution Inc2000-01-052016-04-05Us
Leader Heartburn Relieftablet200 mg/1oralCardinal Health2000-02-042016-04-05Us
Smart Sense Acid Reducertablet200 mg/1oralKmart Corporation2000-01-062016-04-05Us
Sunmark Heartburn Relief Acid Reducertablet200 mg/1oralMc Kesson2003-09-192016-04-05Us
Tagamettablet200 mg/1oralMedtech Products Inc.2012-06-012016-04-05Us
Topcare Heartburn Relieftablet200 mg/1oralTopco Associates LLC2000-02-222016-04-05Us
Up and Up Acid Reducertablet200 mg/1oralTarget Corporation2010-05-122016-04-05Us
International Brands
NameCompany
CimetagJulphar
Tagamet HB200GlaxoSmithKline
UlcedineNot Available
UlcerfenFinadiet
UlcimetFarmasa
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cimetidine Hydrochloride
70059-30-2
Thumb
  • InChI Key: QJHCNBWLPSXHBL-UHFFFAOYSA-N
  • Monoisotopic Mass: 288.092392971
  • Average Mass: 288.8
DBSALT000287
Categories
UNII80061L1WGD
CAS number51481-61-9
WeightAverage: 252.339
Monoisotopic: 252.115715232
Chemical FormulaC10H16N6S
InChI KeyInChIKey=AQIXAKUUQRKLND-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)
IUPAC Name
(Z)-1-cyano-2-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl)guanidine
SMILES
C\N=C(\NCCSCC1=C(C)NC=N1)NC#N
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as imidazoles. These are compounds containing an imidazole ring, which is an aromatic five-member ring with two nitrogen atoms at positions 1 and 3, and three carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassImidazoles
Direct ParentImidazoles
Alternative Parents
Substituents
  • Heteroaromatic compound
  • Imidazole
  • Guanidine
  • Azacycle
  • Dialkylthioether
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Sulfenyl compound
  • Carboximidamide
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Imine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.
PharmacodynamicsCimetidine is a histamine H2-receptor antagonist. It reduces basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin. It is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Cimetidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Cimetidine include an increase in gastric bacterial flora such as nitrate-reducing organisms.
Mechanism of actionCimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.
Related Articles
AbsorptionRapid 60-70%
Volume of distributionNot Available
Protein binding15-20%
Metabolism

Hepatic

Route of eliminationThe principal route of excretion of cimetidine is the urine.
Half life2 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cimetidine Action PathwayDrug actionSMP00232
Cimetidine Metabolism PathwayDrug metabolismSMP00617
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9855
Blood Brain Barrier-0.6782
Caco-2 permeable-0.6358
P-glycoprotein substrateSubstrate0.7887
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.7233
CYP450 2C9 substrateNon-substrate0.8048
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5795
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5773
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9575
Ames testNon AMES toxic0.837
CarcinogenicityNon-carcinogens0.9579
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7341 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7983
hERG inhibition (predictor II)Non-inhibitor0.8745
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Apotex inc
  • Contract pharmacal corp
  • Dava pharmaceuticals inc
  • Endo pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • L perrigo co
  • Perrigo co
  • Pliva inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Teva parenteral medicines inc
  • Actavis mid atlantic llc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Hi tech pharmacal co inc
  • Novex pharma
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
Packagers
Dosage forms
FormRouteStrength
Liquidoral300 mg
Tabletoral400 mg/1
Tablet, film coatedoral200 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral400 mg/1
Tablet, film coatedoral800 mg/1
Solutionoral300 mg/5mL
Tabletoral100 mg
Tabletoral200 mg/1
Tabletoral300 mg
Tabletoral400 mg
Tabletoral600 mg
Tabletoral800 mg
Solutionintramuscular; intravenous150 mg
Tabletoral200 mg
Liquidintravenous6 mg
Liquidintramuscular; intravenous150 mg
Liquidoral60 mg
Prices
Unit descriptionCostUnit
Cimetidine 800 mg tablet2.7USD tablet
Tagamet 400 mg tablet2.51USD tablet
Cimetidine 150 mg/ml vial1.67USD ml
Cimetidine powder1.48USD g
Cimetidine 400 mg tablet1.44USD tablet
Tagamet 300 mg tablet1.28USD tablet
Cimetidine 300 mg tablet0.93USD tablet
Cimetidine 200 mg tablet0.46USD tablet
Cimetidine HCl 300 mg/5ml Solution0.38USD ml
Tagamet hb 200 mg tablet0.37USD tablet
Apo-Cimetidine 800 mg Tablet0.27USD tablet
Mylan-Cimetidine 800 mg Tablet0.27USD tablet
Acid reducer 200 mg tablet0.21USD tablet
Apo-Cimetidine 600 mg Tablet0.18USD tablet
Mylan-Cimetidine 600 mg Tablet0.18USD tablet
Novo-Cimetine 600 mg Tablet0.18USD tablet
Nu-Cimet 600 mg Tablet0.18USD tablet
Apo-Cimetidine 400 mg Tablet0.14USD tablet
Mylan-Cimetidine 400 mg Tablet0.14USD tablet
Novo-Cimetine 400 mg Tablet0.14USD tablet
Nu-Cimet 400 mg Tablet0.14USD tablet
Apo-Cimetidine 200 mg Tablet0.09USD tablet
Apo-Cimetidine 300 mg Tablet0.09USD tablet
Mylan-Cimetidine 300 mg Tablet0.09USD tablet
Novo-Cimetine 300 mg Tablet0.09USD tablet
Nu-Cimet 300 mg Tablet0.09USD tablet
Heartburn relief 200 mg tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point142 °CPhysProp
water solubility9380 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.40HANSCH,C ET AL. (1995)
logS-1.35ADME Research, USCD
Caco2 permeability-5.89ADME Research, USCD
pKa6.8TOMLINSON,E & HAFKENSCHEID,TL (1986)
Predicted Properties
PropertyValueSource
Water Solubility0.816 mg/mLALOGPS
logP0.44ALOGPS
logP-0.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)13.38ChemAxon
pKa (Strongest Basic)6.91ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.89 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.32 m3·mol-1ChemAxon
Polarizability27.47 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-zk40000000-36ce01132725fd5bf5d8View in MoNA
1D NMR1H NMR SpectrumNot Available
References
Synthesis Reference

Saburo Uchikuga, Tomoyasu Tashiro, Yasuko Osawa, “Process for preparing the H.sub.2 -receptor antagonist cimetidine.” U.S. Patent US4413129, issued March, 1972.

US4413129
General References
  1. Michnovicz JJ, Galbraith RA: Cimetidine inhibits catechol estrogen metabolism in women. Metabolism. 1991 Feb;40(2):170-4. [PubMed:1988774 ]
External Links
ATC CodesA02BA01A02BA51
AHFS Codes
  • 56:28.12
PDB EntriesNot Available
FDA labelDownload (420 KB)
MSDSDownload (73.4 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolCimetidine may increase the anticoagulant activities of Acenocoumarol.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Cimetidine.
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Cimetidine.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Cimetidine.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Cimetidine.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Cimetidine.
AmrinoneThe serum concentration of Amrinone can be increased when it is combined with Cimetidine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Cimetidine.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Cimetidine.
BepridilThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Cimetidine.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Cimetidine.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Cimetidine.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Cimetidine.
BupropionThe serum concentration of Cimetidine can be increased when it is combined with Bupropion.
CapecitabineThe serum concentration of the active metabolites of Capecitabine can be increased when Capecitabine is used in combination with Cimetidine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.
CarmustineCimetidine may increase the myelosuppressive activities of Carmustine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Cimetidine.
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Cimetidine.
CefpodoximeCimetidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
CefuroximeCimetidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.
ChlorpropamideThe serum concentration of Chlorpropamide can be increased when it is combined with Cimetidine.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Cimetidine.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cimetidine.
CitalopramThe metabolism of Citalopram can be decreased when combined with Cimetidine.
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Cimetidine.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Cimetidine resulting in a loss in efficacy.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Cimetidine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Cimetidine.
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Cimetidine.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Cimetidine.
DalfampridineThe serum concentration of Dalfampridine can be increased when it is combined with Cimetidine.
DasatinibCimetidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cimetidine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Cimetidine.
DexmethylphenidateCimetidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
DicoumarolCimetidine may increase the anticoagulant activities of Dicoumarol.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Cimetidine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Cimetidine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Cimetidine.
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Cimetidine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cimetidine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Cimetidine.
EpirubicinThe serum concentration of Epirubicin can be increased when it is combined with Cimetidine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Cimetidine.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Cimetidine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cimetidine.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Cimetidine.
FloxuridineThe serum concentration of the active metabolites of Floxuridine can be increased when Floxuridine is used in combination with Cimetidine.
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Cimetidine.
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Cimetidine.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Cimetidine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Cimetidine.
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Cimetidine.
FosphenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Fosphenytoin.
GabapentinThe serum concentration of Gabapentin can be increased when it is combined with Cimetidine.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Cimetidine.
GliclazideThe serum concentration of Gliclazide can be increased when it is combined with Cimetidine.
GlimepirideThe serum concentration of Glimepiride can be increased when it is combined with Cimetidine.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Cimetidine.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Cimetidine.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Cimetidine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Cimetidine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Cimetidine.
Iron DextranCimetidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Cimetidine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Cimetidine.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Cimetidine.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Cimetidine.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Cimetidine.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Cimetidine.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Cimetidine.
LumacaftorThe serum concentration of Cimetidine can be decreased when it is combined with Lumacaftor.
Magnesium SulfateThe serum concentration of Magnesium Sulfate can be increased when it is combined with Cimetidine.
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Cimetidine.
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Cimetidine.
MetforminThe serum concentration of Metformin can be increased when it is combined with Cimetidine.
MethylphenidateCimetidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Cimetidine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Cimetidine.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Cimetidine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Cimetidine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Cimetidine.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Cimetidine.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Cimetidine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Cimetidine.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Cimetidine.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Cimetidine.
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Cimetidine.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Cimetidine.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Cimetidine.
PhenytoinThe risk or severity of adverse effects can be increased when Cimetidine is combined with Phenytoin.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cimetidine.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Cimetidine.
PramipexoleThe serum concentration of Pramipexole can be increased when it is combined with Cimetidine.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Cimetidine.
PrenylamineThe serum concentration of Prenylamine can be increased when it is combined with Cimetidine.
ProcainamideThe serum concentration of Procainamide can be increased when it is combined with Cimetidine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Cimetidine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Cimetidine.
QuinineThe serum concentration of Quinine can be increased when it is combined with Cimetidine.
RanolazineThe serum concentration of Cimetidine can be increased when it is combined with Ranolazine.
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Cimetidine.
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Cimetidine.
RoflumilastThe serum concentration of the active metabolites of Roflumilast can be increased when Roflumilast is used in combination with Cimetidine.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Cimetidine.
SertralineThe metabolism of Sertraline can be decreased when combined with Cimetidine.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Cimetidine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Cimetidine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Cimetidine.
TegafurThe serum concentration of the active metabolites of Tegafur can be increased when Tegafur is used in combination with Cimetidine.
TeriflunomideThe serum concentration of Cimetidine can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Cimetidine can be decreased when it is combined with Tesmilifene.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Cimetidine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Cimetidine.
TolazamideThe serum concentration of Tolazamide can be increased when it is combined with Cimetidine.
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Cimetidine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Cimetidine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Cimetidine.
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Cimetidine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Cimetidine.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Cimetidine.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.
WarfarinCimetidine may increase the anticoagulant activities of Warfarin.
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Cimetidine.
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Cimetidine.
Food Interactions
  • Avoid alcohol.
  • Best effect when taken with food.
  • Limit caffeine intake.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Hernandez-Munoz R, Montiel-Ruiz C, Vazquez-Martinez O: Gastric mucosal cell proliferation in ethanol-induced chronic mucosal injury is related to oxidative stress and lipid peroxidation in rats. Lab Invest. 2000 Aug;80(8):1161-9. [PubMed:10950107 ]
  3. Kuint J, Linder N, Reichman B: Hypoxemia associated with cimetidine therapy in a newborn infant. Am J Perinatol. 1996 Jul;13(5):301-3. [PubMed:8863950 ]
  4. Takahashi HK, Watanabe T, Yokoyama A, Iwagaki H, Yoshino T, Tanaka N, Nishibori M: Cimetidine induces interleukin-18 production through H2-agonist activity in monocytes. Mol Pharmacol. 2006 Aug;70(2):450-3. Epub 2006 May 24. [PubMed:16723495 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Trimethylamine monooxygenase activity
Specific Function:
Involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. It N-oxygenates primary aliphatic alkylamines as well as secondary and tertiary amines. Plays an important role in the metabolism of trimethylamine (TMA), via the production of TMA N-oxide (TMAO). Is also able to perform S-oxidation when acting on sulfide compounds (PubMed:9224773).
Gene Name:
FMO3
Uniprot ID:
P31513
Molecular Weight:
60032.975 Da
References
  1. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082 ]
  2. Cashman JR, Park SB, Berkman CE, Cashman LE: Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact. 1995 Apr 28;96(1):33-46. [PubMed:7720103 ]
  3. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Nadp binding
Specific Function:
This protein is involved in the oxidative metabolism of a variety of xenobiotics such as drugs and pesticides. Form I catalyzes the N-oxygenation of secondary and tertiary amines.
Gene Name:
FMO1
Uniprot ID:
Q01740
Molecular Weight:
60310.285 Da
References
  1. Hai X, Adams E, Hoogmartens J, Van Schepdael A: Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with reference to flavin-containing monooxygenase genetic isoforms. Electrophoresis. 2009 Apr;30(7):1248-57. doi: 10.1002/elps.200800604. [PubMed:19283698 ]
  2. Cashman JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab. 2000 Sep;1(2):181-91. [PubMed:11465082 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res. 2000 Dec;17(12):1456-60. [PubMed:11303953 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14. [PubMed:11042226 ]
  5. Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60. [PubMed:9262363 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365 ]
  2. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291 ]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030 ]
  4. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
  5. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]
  6. Pan BF, Sweet DH, Pritchard JB, Chen R, Nelson JA: A transfected cell model for the renal toxin transporter, rOCT2. Toxicol Sci. 1999 Feb;47(2):181-6. [PubMed:10220855 ]
  7. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071 ]
  8. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
  9. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
  3. Kakehi M, Koyabu N, Nakamura T, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem Biophys Res Commun. 2002 Aug 23;296(3):644-50. [PubMed:12176030 ]
  4. Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM: Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27;272(26):16548-54. [PubMed:9195965 ]
  5. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI: Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998 Nov;287(2):800-5. [PubMed:9808712 ]
  6. Okuda M, Urakami Y, Saito H, Inui K: Molecular mechanisms of organic cation transport in OCT2-expressing Xenopus oocytes. Biochim Biophys Acta. 1999 Mar 4;1417(2):224-31. [PubMed:10082798 ]
  7. Jonker JW, Wagenaar E, Mol CA, Buitelaar M, Koepsell H, Smit JW, Schinkel AH: Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene. Mol Cell Biol. 2001 Aug;21(16):5471-7. [PubMed:11463829 ]
  8. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
  9. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther. 2002 Aug;302(2):510-5. [PubMed:12130709 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Grundemann D, Schechinger B, Rappold GA, Schomig E: Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998 Sep;1(5):349-51. [PubMed:10196521 ]
  2. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924 ]
  3. Kekuda R, Prasad PD, Wu X, Wang H, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta. J Biol Chem. 1998 Jun 26;273(26):15971-9. [PubMed:9632645 ]
  4. Grundemann D, Liebich G, Kiefer N, Koster S, Schomig E: Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. [PubMed:10385678 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Wu X, Prasad PD, Leibach FH, Ganapathy V: cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95. [PubMed:9618255 ]
  2. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100 ]
  3. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther. 1999 Sep;290(3):1482-92. [PubMed:10454528 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  3. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115 ]
  4. Burckhardt BC, Brai S, Wallis S, Krick W, Wolff NA, Burckhardt G: Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol Renal Physiol. 2003 Mar;284(3):F503-9. Epub 2002 Nov 12. [PubMed:12429554 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, Yoo BS, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. [PubMed:11669456 ]
  2. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
  3. Motohashi H, Uwai Y, Hiramoto K, Okuda M, Inui K: Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. [PubMed:15496291 ]
  4. Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
  5. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T: Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. [PubMed:15100168 ]
  6. Nagata Y, Kusuhara H, Endou H, Sugiyama Y: Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol Pharmacol. 2002 May;61(5):982-8. [PubMed:11961115 ]
  7. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, Terasaki T: Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab. 2003 Apr;23(4):432-40. [PubMed:12679720 ]
  8. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H: Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86. [PubMed:11306713 ]
  9. Bakhiya A, Bahn A, Burckhardt G, Wolff N: Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13(5):249-56. [PubMed:14586168 ]
  10. Tahara H, Kusuhara H, Chida M, Fuse E, Sugiyama Y: Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther. 2006 Mar;316(3):1187-94. Epub 2005 Nov 16. [PubMed:16291876 ]
  11. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monovalent cation:proton antiporter activity
Specific Function:
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport...
Gene Name:
SLC47A1
Uniprot ID:
Q96FL8
Molecular Weight:
61921.585 Da
References
  1. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, Kumar V, Stevens JC: Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther. 2010 Sep 1;334(3):936-44. doi: 10.1124/jpet.110.170753. Epub 2010 Jun 2. [PubMed:20519552 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther. 1999 May;289(2):768-73. [PubMed:10215651 ]
  2. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Shibusawa A, Sasaki T, Tokuyama S, Sekine T, Endou H, Yamamoto T: Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. [PubMed:12065749 ]
  2. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11